Key result
Recombinant HCV core protein p116 self-assembles into ~27 nm nanoparticles encapsulating structured RNA and anionic molecules.
Why the study?
RNA-based therapeutics require suitable carriers to protect RNA from enzymatic degradation in vivo, and protein-based nanoparticles offer biocompatible alternatives to synthetic polymers.
Virus-derived protein-assembled particles from HCV core protein show potential as carriers for anionic molecular drugs and structured RNA-based therapeutics.
HCV core protein nanoparticles may enable RNA therapeutic delivery; leaves open translation beyond animal models.
RNA-based molecules have recently become hot candidates to be developed into therapeutic agents. However, successful applications of RNA-based therapeutics might require suitable carriers to protect the RNA from enzymatic degradation by ubiquitous RNases in vivo. Because of their better biocompatibility and biodegradability, protein-based nanoparticles are considered to be alternatives to their synthetic polymer-based counterparts for drug delivery. Hepatitis C virus (HCV) core protein has been suggested to be able to self-assemble into nucleocapsid-like particles in vitro. In this study, the genomic RNA-binding domain of HCV core protein consisting of 116 amino acids (p116) was overexpressed with E. coli for investigation. The recombinant p116 was able to assemble into particles with an average diameter of approximately 27 nm, as visualized by electron microscopy and atomic force microscopy. Measurements with fluorescence spectroscopy, flow cytometry, and fluorescence quenching indicated that the p116-assembled nanoparticles were able to encapsulate small anionic molecules and structured RNA. This study demonstrates methods that exploit the self-assembly nature of a virus-derived protein for nanoparticle production. This study also suggests that the virus-derived protein-assembled particles could possibly be developed into potential carriers for anionic molecular drugs and structured RNA-based therapeutics.
No takes yet. Share an insight, caveat, or question.
Mani et al. (2021) studied this question. Recombinant HCV core protein domain 1 (p116) was evaluated on Encapsulation of negatively charged molecules and structured RNA. Recombinant HCV core protein domain 1 (p116) self-assembled into nanoparticles of approximately 27 nm that successfully encapsulated small anionic molecules and structured RNA.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: